What is the starting dose volume of Semaglutide in milliliters (ml)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Starting Dose Volume of Semaglutide

The starting dose of injectable semaglutide (Wegovy) is 0.25 mg subcutaneously once weekly for 4 weeks, which is administered as a gradual dose titration to minimize gastrointestinal adverse effects. 1

Dosing Schedule for Injectable Semaglutide (Wegovy)

  • The recommended dosing regimen follows a gradual titration schedule:

    • Start with 0.25 mg subcutaneously once weekly for 4 weeks 1
    • Increase to 0.5 mg once weekly for 4 weeks 1
    • Increase to 1.0 mg once weekly for 4 weeks 1
    • Increase to 1.7 mg once weekly for 4 weeks 1
    • Maintenance dose of 2.4 mg once weekly 1
  • This gradual titration is essential to minimize gastrointestinal adverse effects, which are the most common side effects of semaglutide 1, 2

Dosing for Oral Semaglutide (Rybelsus)

  • For oral semaglutide (Rybelsus), the starting dose is 3 mg once daily for one month 3
  • After one month, increase to 7 mg once daily for at least one month 3
  • If additional glycemic control is needed, can increase to 14 mg once daily 3
  • Oral semaglutide must be taken on an empty stomach with no more than 4 ounces (120 mL) of plain water, at least 30 minutes before the first food, beverage, or other oral medications of the day 3, 4

Clinical Considerations for Dosing

  • Some patients may achieve adequate glycemic control at submaximal doses and can continue at that dose long-term 1, 3

  • If a patient misses doses, clinical judgment is needed:

    • If 2 consecutive doses are missed, consider resuming at the same dose or lowering the dose 1
    • If 3 or more consecutive doses are missed, consider restarting the titration schedule 1
  • In clinical trials, semaglutide 0.5 mg and 1.0 mg weekly doses showed similar effectiveness in reducing HbA1c (-2.1% for both doses) and weight (-6.1 kg vs -6.2 kg) in patients with type 2 diabetes 5

Administration Considerations

  • Injectable semaglutide can be administered at any time of day, with or without meals 1

  • For missed doses of injectable semaglutide:

    • If less than 5 days since the missed dose, administer as soon as possible 1
    • If more than 5 days have passed, skip the missed dose 1
  • Proper administration of oral semaglutide is critical for absorption and efficacy; taking with food significantly reduces absorption 3, 4

Safety Considerations

  • The most common adverse effects are gastrointestinal (nausea, vomiting, diarrhea, constipation) but are typically transient and mild-to-moderate in severity 2, 1
  • Use caution when combining with insulin or insulin secretagogues due to potential hypoglycemia risk 1, 3
  • No dosage adjustment is required for patients with renal impairment 1, 3

References

Guideline

Recommended Dosing Regimen for Wegovy (Semaglutide)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Rybelsus Dosing and Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Effect of Various Dosing Conditions on the Pharmacokinetics of Oral Semaglutide, a Human Glucagon-Like Peptide-1 Analogue in a Tablet Formulation.

Diabetes therapy : research, treatment and education of diabetes and related disorders, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.